Emerging treatments for rheumatoid arthritis

American Journal of Medicine

Volumn 102, Issue 1 A, 1997, Pages

  Schiff, Michael ^a,b  

^a CLINICAL RESEARCH UNIT   (United States)

^b Denver Arthritis Clinic PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; COLLAGEN TYPE 2; CORTICOSTEROID; CYCLOSPORIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 4; OMEGA 3 FATTY ACID; PLACEBO; TENIDAP; TUMOR NECROSIS FACTOR ALPHA; ZILEUTON;

BLOOD DYSCRASIA; BONE MARROW DEPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; JOINT DESTRUCTION; LIFESPAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; SYNOVITIS;

EID: 0031055172     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00411-7     Document Type: Conference Paper

References (38)

1. Markenson JA. Worldwide trends in the socioeconomic impact and long-term prognosis of RA. Semin Arthritis Rheum. 1991;21(suppl 1):4-12.
2. Mitchell JM, Burkhauser RV, Pincus T. The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum. 1988;31:348-357.
3. Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum. 1987;30:507-512.
4. Makisara GL, Makisara P. Prognosis of functional capacity and work capacity in rheumatoid arthritis. Clin Rheumatol. 1982;1:117-125.
5. Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol. 1989;79(suppl):67-95.
6. Pincus T, Callahan LF, Vaughn WK. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol. 1987;14:240-251.
7. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J Rheumatol. 1984;11:158-161.
8. Short CL. The antiquity of rheumatoid arthritis. Arthritis Rheum. 1974:17:193-205.
9. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
10. Lawrence JS. Prevalence of rheumatoid arthritis. Ann Rheum Dis. 1961;20:11-17.
11. Lipsky PE. Rheumatoid arthritis. In: Wilson JD, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine, 12th ed. New York: McGraw-Hill, 1991:1437-1443.
12. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277-1289.
13. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis. 1995;54:33-38.
14. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 1978;298:869-887.
15. Boyce E. Pharmacology of antiarthritic drugs. Clin Podiatric Med Surg. 1992;9:327-348.
16. Physicians' Desk Reference, 47th ed. Montvale, NJ: Medical Economics Company, 1993.
17. Hess EV. Rheumatoid arthritis - treatment. In: Schumacher HR, ed. Primer on the Rheumatic Diseases, 9th ed. Richmond, VA: William Byrd Press, 1988:93-99.
18. Dick WC, De Ceulaer K. Nonsteroidal antirheumatic drugs. In: Kelley WN, Harris ED Jr, Ruddy KS, Sledge CB, eds. Textbook of Rheumatology. Philadelphia, PA: WB Saunders, 1981.
19. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16:585-591.
20. Iannuzzi L, Dawson N, Zein N, Juschner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med. 1983;309:1023-1028.
21. Wilske KR, Healey LA. Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis. J Rheumatol. 1990;17(suppl 25):4-7.
22. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol. 1990;17(suppl 22):12-15.
23. Weinblatt ME, Kremer JM, Coblyn JS, et al. Zileuton, a 5-lipoxygenase inhibitor, in rheumatoid arthritis. J Rheumatol. 1992;19:1537-1541.
24. Seiper J, Kary S, Sorensen S, et al. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 1996;39:41-51.
25. Kloppenburg M, Breedveld FC, Miltenburg AM, Dijkmans BA. Antibiotics as disease modifiers in arthritis. Clin Exp Rheumatol. 1993;11(suppl 8):S113-S115.
26. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med. 1995;122:81-89.
27. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum. 1994;37:629-636.
28. Drevlow BE, Lovis R, Haag MA, et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 1996;39:257-265.
29. Buchan G, Barrett K, Turner M, et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-lalpha. Clin Exp Immunol. 1988;73:449-453.
30. Chu CQ, Field M, Feldman M, et al. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991;34:1125-1132.
31. Elliott MJ, Maini RN, Feldman M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum. 1993;36:1681-1690.
32. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025-4031.
33. Williams RO, Feldmann M, Maini RN. Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 1992;89:9784-9788.
34. Elliott MJ, Maini RN, Feldman M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
35. Horneff G. Advances in immunotherapy in rheumatoid arthritis: clinical and immunological findings following treatment with anti-CD4 antibodies. Br J Rheumatol. 1993;32(suppl 14):39-47.
36. Tugwell P. Cyclosporine in rheumatoid arthritis: documented efficacy and safety. Semin Arthritis Rheum. 1992;21(suppl 3):30-38.
37. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med. 1995;333:137-141.
38. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol. 1993;11(suppl 8):S117-S119.